![](/img/cover-not-exists.png)
2108 Subgroup analysis by KRAS status in RAISE: A randomized, double-blind phase III study of irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab or placebo in patients with metastatic colorectal carcinoma progression during or following first-line combination therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine
Van Cutsem, E., Obermannova, R., Bodoky, G., Prausová, J., García-Carbonero, R., Ciuleanu, T., Alfonso, P Garcia, Portnoy, D., Cohn, A., Yamazaki, K., Clingan, P, Yoshino, T., Polikoff, J., Lonardi, SVolume:
51
Language:
english
Journal:
European Journal of Cancer
DOI:
10.1016/S0959-8049(16)31030-9
Date:
September, 2015
File:
PDF, 60 KB
english, 2015